Abstract: Cardiovascular disease is one of the most important causes of death and consumes huge medical resources.Rational drug therapy is the cornerstone of the treatment of cardiovascular disease, but there are significant individual differences in the efficacy and safety of cardiovascular drugs.This article focuses on the effects of some relatively well-documented gene mutations on the pharmacokinetics, pharmacodynamics, clinical endpoint and side effects of beta blockers, statins, clopidogrel, aspirin, warfarin, antiarrhythmic agents, and piperazine diuretics.The latest research progress in the pharmacogenomics of cardiovascular drugs was reviewed, providing reference for genome sequencing-based personalized medicine.